Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months. However, over the last decade, improved understanding of d...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Cancer Research, Statistics, and Treatment |
| Subjects: | |
| Online Access: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2019;volume=2;issue=1;spage=36;epage=53;aulast= |
| _version_ | 1818188314207846400 |
|---|---|
| author | Akhil Rajendra Vanita Noronha Amit Joshi Vijay Maruti Patil Nandini Menon Kumar Prabhash |
| author_facet | Akhil Rajendra Vanita Noronha Amit Joshi Vijay Maruti Patil Nandini Menon Kumar Prabhash |
| author_sort | Akhil Rajendra |
| collection | DOAJ |
| description | Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months. However, over the last decade, improved understanding of driver mutations, especially identification of epidermal growth factor receptor (EGFR) mutation, has changed the treatment landscape of these patients. Our understanding of EGFR mutations has improved tremendously, and we now have three generations of EGFR tyrosine kinase inhibitors, have identified secondary resistance mutations, and have developed agents targeting these resistance mutations, making precision medicine a reality. We review these developments and try to propose an optimal approach toward the management of these patients with EGFR-mutated NSCLC. |
| first_indexed | 2024-12-11T23:24:57Z |
| format | Article |
| id | doaj.art-b294490ef916463f88dbd40c2f91f852 |
| institution | Directory Open Access Journal |
| issn | 2590-3233 2590-3225 |
| language | English |
| last_indexed | 2024-12-11T23:24:57Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Cancer Research, Statistics, and Treatment |
| spelling | doaj.art-b294490ef916463f88dbd40c2f91f8522022-12-22T00:46:15ZengWolters Kluwer Medknow PublicationsCancer Research, Statistics, and Treatment2590-32332590-32252019-01-0121365310.4103/CRST.CRST_51_19Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementAkhil RajendraVanita NoronhaAmit JoshiVijay Maruti PatilNandini MenonKumar PrabhashNon-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months. However, over the last decade, improved understanding of driver mutations, especially identification of epidermal growth factor receptor (EGFR) mutation, has changed the treatment landscape of these patients. Our understanding of EGFR mutations has improved tremendously, and we now have three generations of EGFR tyrosine kinase inhibitors, have identified secondary resistance mutations, and have developed agents targeting these resistance mutations, making precision medicine a reality. We review these developments and try to propose an optimal approach toward the management of these patients with EGFR-mutated NSCLC.http://www.crstonline.com/article.asp?issn=2590-3233;year=2019;volume=2;issue=1;spage=36;epage=53;aulast=egfrlmicnsclcoral tki |
| spellingShingle | Akhil Rajendra Vanita Noronha Amit Joshi Vijay Maruti Patil Nandini Menon Kumar Prabhash Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management Cancer Research, Statistics, and Treatment egfr lmic nsclc oral tki |
| title | Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management |
| title_full | Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management |
| title_fullStr | Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management |
| title_full_unstemmed | Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management |
| title_short | Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management |
| title_sort | epidermal growth factor receptor mutated non small cell lung cancer a primer on contemporary management |
| topic | egfr lmic nsclc oral tki |
| url | http://www.crstonline.com/article.asp?issn=2590-3233;year=2019;volume=2;issue=1;spage=36;epage=53;aulast= |
| work_keys_str_mv | AT akhilrajendra epidermalgrowthfactorreceptormutatednonsmallcelllungcanceraprimeroncontemporarymanagement AT vanitanoronha epidermalgrowthfactorreceptormutatednonsmallcelllungcanceraprimeroncontemporarymanagement AT amitjoshi epidermalgrowthfactorreceptormutatednonsmallcelllungcanceraprimeroncontemporarymanagement AT vijaymarutipatil epidermalgrowthfactorreceptormutatednonsmallcelllungcanceraprimeroncontemporarymanagement AT nandinimenon epidermalgrowthfactorreceptormutatednonsmallcelllungcanceraprimeroncontemporarymanagement AT kumarprabhash epidermalgrowthfactorreceptormutatednonsmallcelllungcanceraprimeroncontemporarymanagement |